⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Olon S.p.A. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Olon S.p.A.
↗Rodano (Milan), Italy
Olon Group is a global leader in the development and production of active pharmaceutical ingredients (APIs) for the CDMO and generic markets. The company integrates chemical synthesis and biological processes, ranging from microbial to mammalian, to provide end-to-end manufacturing services from pre-clinical to commercial scale.
Headquartered in Rodano (Milan), Italy, Olon operates a significant global network including 14 GMP-certified manufacturing facilities and 9 R&D centers. The company is recognized for its expertise in high-potency APIs (HPAPIs), cytotoxic compounds, and antibody-drug conjugate (ADC) bioconjugation, serving both major generic drugmakers and innovator pharmaceutical companies.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$300M-$500M
Founded:1990
Ownership:private
Status:operating
FUNDING
Total Raised:$0
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (CDMO)
Modalities:Small molecule, Biologics, ADC, HPAPI
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Olon USA Inc., P&R Shanghai
Key Partnerships:Global innovator pharmaceutical companies, Generic drug manufacturers
COMPETITION
Position:Leader
Competitors:Symbiotec, Neuland Laboratories, Hikal
LEADERSHIP
Key Executives:
Sabrina Spina - Media Contact
LINKS
Website:olonspa.it
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Olon S.p.A.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.